Form 4: Foghorn Therapeutics Director Scott Biller Acquires 16,000 Stock Options

Sentiment:

SEC Form 4


Director Scott Biller of Foghorn Therapeutics Inc. reports the acquisition of 16,000 stock options on June 26, 2024.

Summary

  • On June 26, 2024, Scott Biller, a director of Foghorn Therapeutics Inc. (FHTX), acquired 16,000 stock options.
  • The options have an exercise price of $5.52.
  • The options become exercisable on June 26, 2025, and expire on June 25, 2034.
  • This transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition.

Positives

  • The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

  • The acquisition of stock options by a director may signal confidence to shareholders.

Key Dates

DateDescription
06/21/2024Date of the Limited Power of Attorney execution.
06/26/2024Date of the stock options transaction.
06/26/2025Date the stock options become exercisable.
06/25/2034Expiration date of the stock options.
06/28/2024Date of the signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.